[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
Gassanov
N
N
Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln. Natig.Gassanov@uk-koeln.de
Caglayan
E
E
Erdmann
E
E
Er
F
F
D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019643:Arthroplasty, Replacement; D001562:Benzimidazoles / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate / Q000502:physiology; D015337:Multicenter Studies as Topic; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D011355:Prodrugs / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013917:Thrombin / Q000037:antagonists & inhibitors*; D054556:Venous Thromboembolism / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D001562:Benzimidazoles; D011355:Prodrugs; D011725:Pyridines; D013917:Thrombin; D000069604:Dabigatran